<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594096</url>
  </required_header>
  <id_info>
    <org_study_id>1575166</org_study_id>
    <nct_id>NCT04594096</nct_id>
  </id_info>
  <brief_title>Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer</brief_title>
  <official_title>Improving Treatment-Related Symptom Management in Adolescents and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the acceptability and feasibility of a telehealth intervention to&#xD;
      improve communication between patients and medical providers in adolescent and young adult&#xD;
      (AYA) cancer patients receiving chemotherapy treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2 telehealth visits with a medical provider (either an MD or NP) after last chemotherapy administration in the cycle, or as otherwise indicated</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Completing the Trial</measure>
    <time_frame>end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)</time_frame>
    <description>&gt;65% of enrolled patients will complete the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survey Response Rate</measure>
    <time_frame>end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)</time_frame>
    <description>&gt;%70% of enrolled patients will complete the survey instruments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)</measure>
    <time_frame>end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)</time_frame>
    <description>A composite score of â‰¥40 (based on 10 items with a Likert scale of 1-5 strongly disagree to strongly agree)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.&#xD;
All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.&#xD;
Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.&#xD;
All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.&#xD;
Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telehealth visits</intervention_name>
    <description>Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle</description>
    <arm_group_label>Delayed Intervention Arm</arm_group_label>
    <arm_group_label>Immediate Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Receiving care as usual from the UC Davis Comprehensive Cancer Center</description>
    <arm_group_label>Delayed Intervention Arm</arm_group_label>
    <arm_group_label>Immediate Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cancer undergoing active treatment and who have received at least two&#xD;
             cycles of chemotherapy&#xD;
&#xD;
          -  Access to Epic MyChart (we will facilitate access to MyChart for interested patients&#xD;
             who are not yet signed up)&#xD;
&#xD;
          -  Access to a smartphone or tablet to access EPIC MyChart telehealth appointments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English or non-Spanish speaking patients&#xD;
&#xD;
          -  Potentially completing therapy during study period (including follow-up period) or&#xD;
             plans to leave UCDCCC during study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Crystal Romero</last_name>
    <phone>916-734-0489</phone>
    <email>ccromero@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Romero</last_name>
      <phone>916-734-0489</phone>
      <email>ccromero@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Elysia Alvarez, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://studypages.com/s/improving-treatment-related-symptom-management-in-adolescents-and-young-adults-with-cancer-888566/</url>
    <description>Learn more or sign up for the study here!</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

